ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The exact role of the BCR-tyrosine kinase domain is unclear, and in a murine model of CML utilizing retroviral introduction of p210BCR–ABL1 deletion mutants into bone marrow cells, it appeared to be dispensable.